The pharmacovigilance environment is evolving from a reactive case processing discipline, to one with greater on risk minimisation and management helping to improve both the engagement between patients and healthcare.
Marketing authorisation holders and regulatory authorities now have a wider range of data and regulatory tools that allow them to scrutinise the safety of products more closely. The Pharmacovigilance Risk Assessment Committee and Medicines and Healthcare products Regulatory Agency are looking to really make a difference in daily healthcare and minimising the risks associated with medicinal products.
There is now a wider scope of challenges for the pharmaceutical industry alongside the ongoing pressure to optimise costs. Pharmacovigilance strategies must be revised and revitalised with smarter spending in mind.
Fill in the form to download our free overview document and see a more detailed description of these changes.